Cost-Effectiveness of a Model Infection Control Program for Preventing Multi-Drug-Resistant Organism Infections in Critically Ill Surgical Patients

JayaramanSudha, P; JiangYushan,; ReschStephen,; AskariReza,; KlompasMichael,

doi:10.1089/sur.2015.222

Cited by 10 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a WTP threshold of 14,000 USD (19,579.43 CAD) per transmission averted, there is a 42% probability of being cost-effective, and 100% probability when WTP thresholds were 22,000 USD (30,767.68 CAD). 49 These similarities suggest that adoption of probiotics for prevention of healthcareassociated infections could be cost-effective.…”

Section: Discussionmentioning

confidence: 99%

Probiotics in hospitalized adult patients: a systematic review of economic evaluations

Lau

Rochwerg

Xie

et al. 2019

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Purpose Probiotics may prevent healthcare-associated infections, such as ventilator-associated pneumonia, Clostridioides difficile-associated diarrhea, and other adverse outcomes. Despite their potential benefits, there are no summative data examining the cost-effectiveness of probiotics in hospitalized patients. This systematic review summarized studies evaluating the economic impact of using probiotics in hospitalized adult patients. Methods We searched MEDLINE, EMBASE, CENTRAL, ACP Journal Club, and other EBM reviews (inception to January 31, 2019) for health economics evaluations examining the use of probiotics in hospitalized adults. Independently and in duplicate, we extracted data study characteristics, risk of bias, effectiveness and total costs (medications, diagnostics/procedures, devices, personnel, hospital) associated with healthcare-associated infections (ventilator-associated pneumonia, Clostridioides difficileassociated diarrhea and antibiotic-associated diarrhea). We used Grading of Recommendations Assessment, Development and Evaluation methods to assess certainty in the overall cost-effectiveness evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Probiotics in hospitalized adult patients: a systematic review of economic evaluations

Lau

Rochwerg

Xie

et al. 2019

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

“…Furthermore, many studies have evaluated the results of MDR‐GNB induced infections, which can lead to high morbidity and to mortality of between 40% and 50% (Ozsurekci et al, ). A study in the United States showed that the mortality rate of ICU patients increases by 22% for those with Acinetobacter infection, with an additional hospitalization cost of $30 000 (Jayaraman, Jiang, Resch, Askari, & Klompas, ). MDR‐GNB infections are mainly transmitted through contact, and the most frequent source of direct contact with ICU patients is the nurse.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for multidrug‐resistant Gram‐negative bacteria infection in intensive care units: A meta‐analysis

Ang

Sun

2018

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…Interventions including proactive infection control, hand hygiene and gown usage were cost-effective at country WTP thresholds (figure 4B). [62][63][64] For instance, Luangasanatip et al found that 20% compliance in healthcare hygiene protocol, versus 10%, was associated with reductions in MRSA bloodstream infections (BSIs) and ICERs of $1160 and $835 per QALY in paediatric and adult ICUs, respectively. 62 Gown usage for 18 months was linked to 58 VRE cases averted in a hospital ICU in the USA (ICER=$2939 per case averted).…”

Section: Hygiene and Sanitationmentioning

confidence: 99%

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Allel,

Hernández-Leal,

Naylor

et al. 2024

BMJ Glob Health

View full text Add to dashboard Cite

IntroductionLimited information on costs and the cost-effectiveness of hospital interventions to reduce antibiotic resistance (ABR) hinder efficient resource allocation.MethodsWe conducted a systematic literature review for studies evaluating the costs and cost-effectiveness of pharmaceutical and non-pharmaceutical interventions aimed at reducing, monitoring and controlling ABR in patients. Articles published until 12 December 2023 were explored using EconLit, EMBASE and PubMed. We focused on critical or high-priority bacteria, as defined by the WHO, and intervention costs and incremental cost-effectiveness ratio (ICER). Following Preferred Reporting Items for Systematic review and Meta-Analysis guidelines, we extracted unit costs, ICERs and essential study information including country, intervention, bacteria-drug combination, discount rates, type of model and outcomes. Costs were reported in 2022 US dollars ($), adopting the healthcare system perspective. Country willingness-to-pay (WTP) thresholds from Woodset al2016 guided cost-effectiveness assessments. We assessed the studies reporting checklist using Drummond’s method.ResultsAmong 20 958 articles, 59 (32 pharmaceutical and 27 non-pharmaceutical interventions) met the inclusion criteria. Non-pharmaceutical interventions, such as hygiene measures, had unit costs as low as $1 per patient, contrasting with generally higher pharmaceutical intervention costs. Several studies found that linezolid-based treatments for methicillin-resistantStaphylococcus aureuswere cost-effective compared with vancomycin (ICER up to $21 488 per treatment success, all 16 studies’ ICERs<WTP). Infection control measures such as hand hygiene and gown usage (ICER=$1160/QALY or $4949 per ABR case averted, all ICERs<WTP) and PCR or chromogenic agar screening for ABR detection were highly cost-effective (eg, ICER=$1206 and $1115 per life-year saved in Europe and the USA). Comparisons were hindered by within-study differences.ConclusionRobust information on ABR interventions is critical for efficient resource allocation. We highlight cost-effective strategies for mitigating ABR in hospitals, emphasising substantial knowledge gaps, especially in low-income and middle-income countries. Our study serves as a resource for guiding future cost-effectiveness study design and analyses.PROSPERO registration numberCRD42020341827 and CRD42022340064

show abstract

Cost-Effectiveness of a Model Infection Control Program for Preventing Multi-Drug-Resistant Organism Infections in Critically Ill Surgical Patients

Cited by 10 publications

References 25 publications

Probiotics in hospitalized adult patients: a systematic review of economic evaluations

Probiotics in hospitalized adult patients: a systematic review of economic evaluations

Risk factors for multidrug‐resistant Gram‐negative bacteria infection in intensive care units: A meta‐analysis

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Contact Info

Product

Resources

About